ClinicalTrials.gg
CompletedNCT02091375Updated Sep 28, 2022Results posted

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

A Phase 3 interventional study of GWP42003-P 20 mg/kg/day Dose and Placebo control in Epilepsy and Dravet Syndrome, sponsored by Jazz Pharmaceuticals. Completed at 22 sites in 4 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2022-09-28.

Primary conditionEpilepsies, MyoclonicRegistry: EpilepsyReclassifiedWhy we changed it
Registry
Epilepsy — the first condition term the registry derived for this study.
ClinicalTrials.gg
Epilepsies, Myoclonic
Why
  1. The study's listed conditions name Epilepsies, Myoclonic, a narrower term within Epilepsy.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing cannabidiol in Epilepsies, Myoclonic — 1 open to participants now, 2 under way, none of them phase 3. Cannabidiol · Epilepsies, Myoclonic.

Enrollment
4th of 14
120 · median 30
Started
2015
with 2 others
Phase 3
8 of 14
none open now
Registered
1st of 14
by date
Lead sponsor
6 of 14
Jazz Pharmaceuticals

Among the 14 studies testing cannabidiol in Epilepsies, Myoclonic, this one is the 4th largest by enrollment, is one of 3 that started in 2015, is one of 8 in phase 3, and was the 1st registered.

Epilepsies, Myoclonic

92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.

Browse Epilepsies, Myoclonic studies →

Open to participants now

1 of the 14 studies testing cannabidiol in Epilepsies, Myoclonic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About cannabidiol

Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing cannabidiol in Epilepsies, Myoclonic, or all of them as a file.
02

Study summary

To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.

Read the detailed description

GWEP1332 Part B recruited an entirely new group of participants than GWEP1332 Part A. Participants who failed the entry criteria for Part A were eligible to take part in Part B.

Part B was a 1:1 randomized, double-blind, placebo-controlled, 14-week comparison of GWP42003-P versus placebo. The aim of Part B was to assess the antiepileptic efficacy of GWP42003-P as an adjunctive antiepileptic treatment compared with placebo, with respect to the percentage change from baseline during the treatment period of the study in convulsive seizure frequency in children and young adults.

Following the establishment of initial eligibility and baseline measurements, participants entered Part B and began a 28-day baseline observation period.

Eligible participants were then randomized to receive either GWP42003-P or placebo on a 1:1 basis and titrated up to the target dose that was identified in Part A (up to 20 milligrams [mg] per kilogram [kg] per day), which was confirmed following completion of Part A by an independent Data Safety Monitoring Committee who reviewed unblinded safety and pharmacokinetic data from Part A.

Participants received investigational medicinal product for 14 weeks, consisting of a titration period followed by a 12-week maintenance period.

Efficacy and safety were monitored at various clinic visits and via telephone. After 14 weeks of treatment, all participants were offered the option of entering an open label extension (OLE) study. Entry was within seven days of the final treatment visit. Participants who did not immediately enter the OLE study commenced a down-titration taper period lasting up to 10 days. The taper period was interrupted if the participant wished to enter the open label extension study within the seven-day timeframe.

For participants who opted not to enter the OLE study, a follow-up telephone call was made 28 days after the end of dosing and weekly safety telephone calls were made during the 28-day follow-up period.

03

Conditions studied

  • Epilepsy
  • Dravet Syndrome

Browse trials for

Keywords

  • Cannabidiol
  • CBD
  • Epidiolex
  • GWP42003-P
04

In context

Epilepsies, Myoclonic Reclassified

92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.

This study's enrollment of 120 is above the median of 31 across 56 interventional studies indexed under Epilepsies, Myoclonic.

Browse Epilepsies, Myoclonic studies →

Lead sponsor

Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.

Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.

Compared within Epilepsies, Myoclonic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants were male or female aged between 2 and 18 years (inclusive).
  • Participants had a documented history of Dravet Syndrome that was not completely controlled by current antiepileptic drugs.
  • Participants took one or more antiepileptic drugs at a dose that had been stable for at least four weeks.
  • All medications or interventions for epilepsy (including ketogenic diet and vagus nerve stimulation) were stable for four weeks prior to screening and participants were willing to maintain a stable regimen throughout the study.

Key Exclusion Criteria:

  • Participants had unstable medical conditions other than epilepsy.
  • Participants had clinically relevant symptoms or a clinically significant illness in the four weeks prior to screening or randomization, other than epilepsy.
  • Participants were currently using or had in the past used recreational or medicinal cannabis or synthetic cannabinoid based medications (including Sativex®) within the three months prior to study entry and were unwilling to abstain for the duration for the study.
  • Participants had any known or suspected to cannabinoids or any of the of the medicinal products.
  • Participants had been part of a previous clinical trial involving another investigational product in the previous six months.
  • There were plans for the participants to travel outside their country of residence during the study.
  • Participants previously randomized into this study. In particular, participants who participated in Part A of the study could not enter Part B.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    GWP42003-P 20 mg/kg/day Dose

    Participants received 20 mg/kg/day of GWP42003-P administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.

    Drug: GWP42003-P 20 mg/kg/day Dose

  • Placebo comparator
    Placebo

    Participants received placebo (0 mg/mL CBD), volume-matched to the 20 mg/kg/day dose level, administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day of the matched dose) period.

    Drug: Placebo control

Interventions

  • DrugGWP42003-P 20 mg/kg/day Dose

    Drug page: Cannabidiol

    GWP42003-P was an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) dissolved in the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).

    Also known as: Cannabidiol, Epidiolex

  • DrugPlacebo control

    Placebo oral solution contained the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).

    Also known as: Placebo

07

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period

    Convulsive seizures (atonic, clonic, tonic, or tonic-clonic) were recorded by the participant or caregiver using an interactive voice response system (IVRS) diary. Percentage change from baseline was calculated as: (\[frequency during the treatment period - frequency during baseline\]/frequency during baseline) \* 100. The frequency during each period was based on 28-day averages and calculated as: (number of seizures in the period/number of reported days in the IVRS period) \* 28. Baseline included all available data prior to Day 1 (28-day average). Negative percentages show an improvement from baseline.

    Time frame: Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)

Secondary outcomes

  1. Number Of Participants With A ≥50% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period

    Convulsive seizures (atonic, clonic, tonic, or tonic-clonic) were recorded by the participant or caregiver using an IVRS diary. Percentage change from baseline was calculated as per the primary outcome measure.

    Time frame: Baseline to EOT (Day 99) or ET

  2. Number of Participants With A ≥25%, ≥75% Or 100% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period

    Convulsive seizures (atonic, clonic, tonic, or tonic-clonic) were recorded by the participant or caregiver using an IVRS diary. Percentage change from baseline was calculated as per the primary outcome measure.

    Time frame: Baseline to EOT (Day 99) or ET

  3. Percentage Change From Baseline In Non-Convulsive Seizure Frequency During The Treatment Period

    Non-convulsive seizures (myoclonic, partial, or absence) were recorded by the participant or caregiver using an IVRS diary. Percentage change from baseline was calculated as per the primary outcome measure. Only participants with non-convulsive seizures during the baseline period were included. Negative percentages show an improvement from baseline.

    Time frame: Baseline to EOT (Day 99) or ET

  4. Caregiver Global Impression Of Change In Seizure Duration (CGICSD)

    Seizure duration was assessed qualitatively using the CGICSD. Caregivers were asked "Since the patient started treatment, please assess the average duration of the patient's seizures (comparing their condition now to their condition before treatment)"; responses included decrease, no change, or increase in average duration. For each seizure type, only participants with at least 1 seizure for the corresponding seizure type, reported at any time during the study, were included.

    Time frame: Baseline to EOT (Day 99) or ET

  5. Number Of Participants Using Rescue Medication

    The use of rescue medication was recorded by the participant or caregiver using a paper diary.

    Time frame: Baseline to EOT (Day 99) or ET

  6. Number Of Participants With Inpatient Hospitalizations Due To Epilepsy

    Inpatient hospitalizations due to epilepsy were recorded by the participant or caregiver and through the serious adverse events (SAE) reporting process.

    Time frame: Baseline to Safety Follow-up (Day 137)

  7. Change From Baseline In Sleep Disruption 0 To 10 Numerical Rating Scale (0 to 10 NRS) Score

    The sleep disruption 0 to 10 NRS questionnaire was completed by the participant's caregiver. The caregiver was asked 'On a scale of '0 to 10', please indicate the number that best describes your child's sleep disruption in the last week.' The markers ranged from 0 = 'slept extremely well' to 10 = 'unable to sleep at all'. The change from baseline in the sleep disruption 0 to 10 numerical rating scale score was analyzed using an analysis of covariance (ANCOVA) model with baseline and age group (2 to 5 years, 6 to 12 years and 13 to 18 years) as covariates and treatment group as a fixed factor. A negative change from baseline represents an improvement in sleep. Last visit for endpoints assessed at clinic visits was defined as the last scheduled visit (not including the end of taper or safety follow-up visits) at which participant's last evaluation was performed.

    Time frame: Baseline to Last Visit (Day 99) or ET

  8. Change From Baseline In Epworth Sleepiness Scale (ESS) Score

    The ESS questionnaire was completed by the participant's caregiver. The change from baseline in the ESS score was analyzed using an ANCOVA model with baseline and age group (2 to 5 years, 6- to 2 years and 13 to 18 years) as covariates and treatment group as a fixed factor. The total score was the sum of the 8 item-scores and ranged from 0 to 24. A higher total score represents greater levels of daytime sleepiness.

    Time frame: Baseline to Last Visit (Day 99) or ET

  9. Change From Baseline In Quality Of Life In Childhood Epilepsy (QOLCE) Score

    The QOLCE questionnaire was completed by the parent or caregiver of participants aged 4 years and above. The change from baseline in the overall quality of life score was analyzed using an ANCOVA model with baseline and age group (2 to 5 years, 6 to 12 years and 13 to 18 years) as covariates and treatment group as a fixed factor. Zero represents the lowest or poorest category and 100 represents the highest level of functioning. The overall quality of life score was calculated by taking the mean of the subscale scores.

    Time frame: Baseline to EOT (Day 99) or ET

  10. Change From Baseline In Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Score

    The Vineland-II scores (standard scores and adaptive levels for each adaptive behavior domain, the adaptive behavior composite, and the maladaptive behavior index score and level) were assessed by the participant's caregiver. Scores were analyzed using an ANCOVA model with baseline and age group (2 to 5 years, 6 to 12 years, and 13 to 18 years) as covariates and treatment group as a fixed factor. Higher scores represent greater levels of functioning except for the maladaptive behavior index, for which a negative change from baseline represents an improvement in condition.

    Time frame: Baseline to Last Visit (Day 99) or ET

  11. Caregiver Global Impression Of Change (CGIC)

    The CGIC was used to assess the participant's overall condition on a 7-point scale using the markers "very much improved, much improved, slightly improved, no change, slightly worse, much worse, or very much worse" (1 = very much improved; 7 = very much worse). On Day 1 (prior to starting IMP), the caregiver was asked to write a brief description of the participant's overall condition as a memory aid for the CGIC questionnaire at subsequent visits.

    Time frame: Baseline to Last Visit (Day 99) or ET

08

Results

Posted Jul 20, 2018

Participant flow

Participant flow — Overall Study
MilestoneGWP42003-P 20 mg/kg/Day DosePlacebo
Started6159
Safety analysis set6159
Intention to treat (itt) analysis set6159
Completed5256
Not completed93
Withdrew: Adverse event81
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject01
Withdrew: Withdrawn by the investigator10

Outcome measures

PrimaryPercentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period

Convulsive seizures (atonic, clonic, tonic, or tonic-clonic) were recorded by the participant or caregiver using an interactive voice response system (IVRS) diary. Percentage change from baseline was calculated as: (\[frequency during the treatment period - frequency during baseline\]/frequency during baseline) \* 100. The frequency during each period was based on 28-day averages and calculated as: (number of seizures in the period/number of reported days in the IVRS period) \* 28. Baseline included all available data prior to Day 1 (28-day average). Negative percentages show an improvement from baseline.

Time frame:
Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)
Reported as:
Median · percent change
Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period
percent changeGWP42003-P 20 mg/kg/Day DosePlacebo
Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period-38.94 (-69.53 to -4.83)-13.29 (-52.53 to 20.20)
Statistical analysis
  • GWP42003-P 20 mg/kg/Day Dose vs Placebo · Wilcoxon rank-sum test · p = 0.0123 · Median difference (final values): -22.79 · 95% CI -41.06 to -5.43Calculated using the Hodges-Lehmann approach.
SecondaryNumber Of Participants With A ≥50% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period

Convulsive seizures (atonic, clonic, tonic, or tonic-clonic) were recorded by the participant or caregiver using an IVRS diary. Percentage change from baseline was calculated as per the primary outcome measure.

Time frame:
Baseline to EOT (Day 99) or ET
Reported as:
Count of participants · Participants
Number Of Participants With A ≥50% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period
ParticipantsGWP42003-P 20 mg/kg/Day DosePlacebo
Number Of Participants With A ≥50% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period2616
Statistical analysis
  • GWP42003-P 20 mg/kg/Day Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.0784 · Odds ratio (or): 2.00 · 95% CI 0.93 to 4.30Stratified by age group (2-5 years, 6-12 years, and 13-18 years).
SecondaryNumber of Participants With A ≥25%, ≥75% Or 100% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period

Convulsive seizures (atonic, clonic, tonic, or tonic-clonic) were recorded by the participant or caregiver using an IVRS diary. Percentage change from baseline was calculated as per the primary outcome measure.

Time frame:
Baseline to EOT (Day 99) or ET
Reported as:
Count of participants · Participants
Number of Participants With A ≥25%, ≥75% Or 100% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period
ParticipantsGWP42003-P 20 mg/kg/Day DosePlacebo
≥25% Reduction3826
≥75% Reduction147
100% Reduction30
SecondaryPercentage Change From Baseline In Non-Convulsive Seizure Frequency During The Treatment Period

Non-convulsive seizures (myoclonic, partial, or absence) were recorded by the participant or caregiver using an IVRS diary. Percentage change from baseline was calculated as per the primary outcome measure. Only participants with non-convulsive seizures during the baseline period were included. Negative percentages show an improvement from baseline.

Time frame:
Baseline to EOT (Day 99) or ET
Reported as:
Median · percent change
Percentage Change From Baseline In Non-Convulsive Seizure Frequency During The Treatment Period
percent changeGWP42003-P 20 mg/kg/Day DosePlacebo
Percentage Change From Baseline In Non-Convulsive Seizure Frequency During The Treatment Period-40.16 (-92.1 to -3.6)-34.69 (-97.5 to -0.7)
SecondaryCaregiver Global Impression Of Change In Seizure Duration (CGICSD)

Seizure duration was assessed qualitatively using the CGICSD. Caregivers were asked "Since the patient started treatment, please assess the average duration of the patient's seizures (comparing their condition now to their condition before treatment)"; responses included decrease, no change, or increase in average duration. For each seizure type, only participants with at least 1 seizure for the corresponding seizure type, reported at any time during the study, were included.

Time frame:
Baseline to EOT (Day 99) or ET
Reported as:
Count of participants · Participants
Caregiver Global Impression Of Change In Seizure Duration (CGICSD)
ParticipantsGWP42003-P 20 mg/kg/Day DosePlacebo
Tonic-Clonic Seizures — Decrease in average duration178
Tonic-Clonic Seizures — No change in average duration3231
Tonic-Clonic Seizures — Increase in average duration02
Tonic Seizures — Decrease in average duration42
Tonic Seizures — No change in average duration812
Tonic Seizures — Increase in average duration01
Clonic Seizures — Decrease in average duration53
Clonic Seizures — No change in average duration63
Clonic Seizures — Increase in average duration01
Atonic Seizures — Decrease in average duration22
Atonic Seizures — No change in average duration13
Atonic Seizures — Increase in average duration02
Myoclonic Seizures — Decrease in average duration43
Myoclonic Seizures — No change in average duration1012
Myoclonic Seizures — Increase in average duration03
Countable Partial Seizures — Decrease in average duration52
Countable Partial Seizures — No change in average duration79
Countable Partial Seizures — Increase in average duration02
Other Partial Seizures — Decrease in average duration03
Other Partial Seizures — No change in average duration32
Other Partial Seizures — Increase in average duration00
Absence Seizures — Decrease in average duration46
Absence Seizures — No change in average duration1112
Absence Seizures — Increase in average duration11
SecondaryNumber Of Participants Using Rescue Medication

The use of rescue medication was recorded by the participant or caregiver using a paper diary.

Time frame:
Baseline to EOT (Day 99) or ET
Reported as:
Count of participants · Participants
Number Of Participants Using Rescue Medication
ParticipantsGWP42003-P 20 mg/kg/Day DosePlacebo
Number Of Participants Using Rescue Medication3641
SecondaryNumber Of Participants With Inpatient Hospitalizations Due To Epilepsy

Inpatient hospitalizations due to epilepsy were recorded by the participant or caregiver and through the serious adverse events (SAE) reporting process.

Time frame:
Baseline to Safety Follow-up (Day 137)
Reported as:
Number · participants
Number Of Participants With Inpatient Hospitalizations Due To Epilepsy
participantsGWP42003-P 20 mg/kg/Day DosePlacebo
Caregiver/participant-reported51
Investigator-reported (serious TEAE)21
SecondaryChange From Baseline In Sleep Disruption 0 To 10 Numerical Rating Scale (0 to 10 NRS) Score

The sleep disruption 0 to 10 NRS questionnaire was completed by the participant's caregiver. The caregiver was asked 'On a scale of '0 to 10', please indicate the number that best describes your child's sleep disruption in the last week.' The markers ranged from 0 = 'slept extremely well' to 10 = 'unable to sleep at all'. The change from baseline in the sleep disruption 0 to 10 numerical rating scale score was analyzed using an analysis of covariance (ANCOVA) model with baseline and age group (2 to 5 years, 6 to 12 years and 13 to 18 years) as covariates and treatment group as a fixed factor. A negative change from baseline represents an improvement in sleep. Last visit for endpoints assessed at clinic visits was defined as the last scheduled visit (not including the end of taper or safety follow-up visits) at which participant's last evaluation was performed.

Time frame:
Baseline to Last Visit (Day 99) or ET
Reported as:
Least squares mean · units on a scale
Change From Baseline In Sleep Disruption 0 To 10 Numerical Rating Scale (0 to 10 NRS) Score
units on a scaleGWP42003-P 20 mg/kg/Day DosePlacebo
Change From Baseline In Sleep Disruption 0 To 10 Numerical Rating Scale (0 to 10 NRS) Score-0.7 (-1.5 to 0.1)-0.3 (-1.1 to 0.5)
SecondaryChange From Baseline In Epworth Sleepiness Scale (ESS) Score

The ESS questionnaire was completed by the participant's caregiver. The change from baseline in the ESS score was analyzed using an ANCOVA model with baseline and age group (2 to 5 years, 6- to 2 years and 13 to 18 years) as covariates and treatment group as a fixed factor. The total score was the sum of the 8 item-scores and ranged from 0 to 24. A higher total score represents greater levels of daytime sleepiness.

Time frame:
Baseline to Last Visit (Day 99) or ET
Reported as:
Least squares mean · units on a scale
Change From Baseline In Epworth Sleepiness Scale (ESS) Score
units on a scaleGWP42003-P 20 mg/kg/Day DosePlacebo
Change From Baseline In Epworth Sleepiness Scale (ESS) Score0.82 (-0.36 to 1.99)-0.69 (-1.90 to 0.52)
SecondaryChange From Baseline In Quality Of Life In Childhood Epilepsy (QOLCE) Score

The QOLCE questionnaire was completed by the parent or caregiver of participants aged 4 years and above. The change from baseline in the overall quality of life score was analyzed using an ANCOVA model with baseline and age group (2 to 5 years, 6 to 12 years and 13 to 18 years) as covariates and treatment group as a fixed factor. Zero represents the lowest or poorest category and 100 represents the highest level of functioning. The overall quality of life score was calculated by taking the mean of the subscale scores.

Time frame:
Baseline to EOT (Day 99) or ET
Reported as:
Least squares mean · units on a scale
Change From Baseline In Quality Of Life In Childhood Epilepsy (QOLCE) Score
units on a scaleGWP42003-P 20 mg/kg/Day DosePlacebo
Change From Baseline In Quality Of Life In Childhood Epilepsy (QOLCE) Score5.6 (1.9 to 9.3)4.1 (0.2 to 8.0)
SecondaryChange From Baseline In Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Score

The Vineland-II scores (standard scores and adaptive levels for each adaptive behavior domain, the adaptive behavior composite, and the maladaptive behavior index score and level) were assessed by the participant's caregiver. Scores were analyzed using an ANCOVA model with baseline and age group (2 to 5 years, 6 to 12 years, and 13 to 18 years) as covariates and treatment group as a fixed factor. Higher scores represent greater levels of functioning except for the maladaptive behavior index, for which a negative change from baseline represents an improvement in condition.

Time frame:
Baseline to Last Visit (Day 99) or ET
Reported as:
Least squares mean · units on a scale
Change From Baseline In Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Score
units on a scaleGWP42003-P 20 mg/kg/Day DosePlacebo
Communication Domain Standard Score-0.8 (-3.2 to 1.5)3.0 (0.8 to 5.3)
Daily Living Skills Domain Standard Score-0.8 (-4.0 to 2.4)-0.8 (-4.1 to 2.6)
Socialization Domain Standard Score-0.6 (-4.6 to 3.5)-0.6 (-4.0 to 2.7)
Motor Skills Domain Standard Score-2.5 (-5.5 to 0.5)1.7 (-1.1 to 4.5)
Adaptive Behavior Composite Standard Score-2.0 (-5.2 to 1.1)0.6 (-2.1 to 3.3)
Maladaptive Behavior Index v-Scale Score-0.3 (-0.7 to 0.1)-0.4 (-0.8 to 0.0)
SecondaryCaregiver Global Impression Of Change (CGIC)

The CGIC was used to assess the participant's overall condition on a 7-point scale using the markers "very much improved, much improved, slightly improved, no change, slightly worse, much worse, or very much worse" (1 = very much improved; 7 = very much worse). On Day 1 (prior to starting IMP), the caregiver was asked to write a brief description of the participant's overall condition as a memory aid for the CGIC questionnaire at subsequent visits.

Time frame:
Baseline to Last Visit (Day 99) or ET
Reported as:
Count of participants · Participants
Caregiver Global Impression Of Change (CGIC)
ParticipantsGWP42003-P 20 mg/kg/Day DosePlacebo
Very Much Improved94
Much Improved104
Slightly Improved1812
No Change1531
Slightly Worse36
Much Worse41
Very Much Worse10

Adverse events

Collected over Day 1 (after dosing) to Day 137. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GWP42003-P 20 mg/kg/Day Dose—10/61 (16.4%)46/61 (75.4%)
Placebo—3/59 (5.1%)28/59 (47.5%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventGWP42003-P 20 mg/kg/Day DosePlacebo
Status epilepticusNervous system disorders3/613/59
SomnolenceNervous system disorders3/610/59
ConvulsionNervous system disorders2/611/59
Respiratory failureRespiratory, thoracic and mediastinal disorders1/611/59
Abdominal distensionGastrointestinal disorders1/610/59
Abdominal painGastrointestinal disorders1/610/59
Gastrointestinal haemorrhageGastrointestinal disorders1/610/59
AstheniaGeneral disorders1/610/59
FatigueGeneral disorders1/610/59
Lower respiratory tract infectionInfections and infestations1/610/59
Most frequent other events
Showing 10 of 16
Most frequent other events
EventGWP42003-P 20 mg/kg/Day DosePlacebo
DiarrhoeaGastrointestinal disorders19/616/59
SomnolenceNervous system disorders19/616/59
Decreased appetiteMetabolism and nutrition disorders16/613/59
FatigueGeneral disorders11/612/59
VomitingGastrointestinal disorders9/613/59
PyrexiaGeneral disorders9/615/59
Upper respiratory tract infectionInfections and infestations7/615/59
LethargyNervous system disorders7/613/59
ConvulsionNervous system disorders5/612/59
Gamma-glutamyltransferase increasedInvestigations4/610/59

Baseline characteristics

Safety Analysis Set: included all participants randomized to treatment who received at least 1 dose of IMP. Participants were analyzed according to the actual treatment they received.

Age, Continuous
Age, Continuous(Years)GWP42003-P 20 mg/kg/Day DosePlaceboTotal
Mean9.736 ± 4.73099.779 ± 4.85059.757 ± 4.7699
Sex: Female, Male
Sex: Female, Male(Participants)GWP42003-P 20 mg/kg/Day DosePlaceboTotal
Female263258
Male352762
09

Study locations

22 sites
  • Miami, Florida 33155, United States
  • Orlando, Florida 32819, United States
  • Atlanta, Georgia 30328, United States
  • Chicago, Illinois 60611, United States
  • Iowa City, Iowa 52242, United States
  • Boston, Massachusetts 02114, United States
  • Rochester, Minnesota 55905, United States
  • New York, New York 10016, United States
  • Winston-Salem, North Carolina 27408, United States
  • Columbus, Ohio 43205, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Houston, Texas 77030, United States
  • Salt Lake City, Utah 84113, United States
  • Marseille, 13385, France
  • Paris, 75015, France
  • Strasbourg, 67098, France
  • Toulouse, 70034, France
  • Gdańsk, 80-952, Poland
  • Kraków, 30-349, Poland
  • Glasgow, G51 4TF, United Kingdom
  • Liverpool, L12 2AP, United Kingdom
  • London, WC1N 3JH, United Kingdom
10

References and documents

Publications

  • Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S; Cannabidiol in Dravet Syndrome Study Group. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017 May 25;376(21):2011-2020. doi: 10.1056/NEJMoa1611618. PubMed 28538134 ↗
  • Madan Cohen J, Checketts D, Dunayevich E, Gunning B, Hyslop A, Madhavan D, Villanueva V, Zolnowska M, Zuberi SM. Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials. Epilepsia. 2021 Sep;62(9):2218-2227. doi: 10.1111/epi.16974. Epub 2021 Jul 15. PubMed 34265088 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Nov 2015, 7 months.

Results were first posted in Jul 2018, 2 years 7 months after primary completion. A results delay was requested in Jun 2016.

Of 15 phase 3 interventional studies under Epilepsies, Myoclonic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 72. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2014
First posted
Mar 19, 2014
StartActual
Mar 30, 2015
Primary completionActual
Nov 26, 2015
CompletionActual
Nov 26, 2015
Results delay requested
Jun 17, 2016
Results first posted
Jul 20, 2018
Last update
Sep 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02091375
Responsible party
Sponsor
First posted
Mar 19, 2014
Start date
Mar 30, 2015
Primary completion
Nov 26, 2015
Completion
Nov 26, 2015
Results posted
Jul 20, 2018
Last update
Sep 28, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion